Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer
Ribociclib with spartalizumab and fulvestrant showed limited efficacy and elevated hepatotoxicity, precluding further development. Correlative analyses revealed treatment-induced immunological effects, and genomic alterations associated with PFS.
Authors
- Stephanie K. Dougan (ORCID: https://orcid.org/0000-0002-2263-363X)
- Shom Goel (ORCID: https://orcid.org/0000-0001-8329-9084)
- Ana C. Garrido-Castro (ORCID: https://orcid.org/0000-0002-5989-6636)
- Elizabeth A. Mittendorf (ORCID: https://orcid.org/0000-0002-9762-8536)
- Molly K. DiLullo (ORCID: https://orcid.org/0009-0005-1036-796X)
- Eileen Wrabel
- Lestat R. Ali (ORCID: https://orcid.org/0000-0003-2673-1592)
- Geoffrey Ira Shapiro (ORCID: https://orcid.org/0000-0002-3331-4095)
- Nabihah Tayob (ORCID: https://orcid.org/0000-0001-6088-167X)
- Sara M. Tolaney (ORCID: https://orcid.org/0000-0002-5940-8671)
- Amy J. Williams (ORCID: https://orcid.org/0000-0001-6299-0845)
- Christina I. Herold (ORCID: https://orcid.org/0009-0002-0177-0253)
- Heather A. Parsons (ORCID: https://orcid.org/0000-0001-8178-6612)
- Noah Graham (ORCID: https://orcid.org/0009-0009-0622-683X)
- Tianyu Li (ORCID: https://orcid.org/0000-0003-3719-4892)
- Khanh Do (ORCID: https://orcid.org/0000-0001-7834-3781)
- Jennifer Desrosiers
- Joyce F Liu
Institutions
- Uppsala University (SE)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Peter MacCallum Cancer Centre (AU)
- Dana-Farber Cancer Institute (US)
- Dana-Farber/Harvard Cancer Center (US)
- Takeda (United States) (US)
- Dana-Farber Brigham Cancer Center (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1136/jitc-2024-010430
- Citations
- 10
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 15.18
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Novartis
- Sanofi
- Gilead Sciences
- Regeneron Pharmaceuticals
- Merck KGaA
- Exelixis
- Jazz Pharmaceuticals
- Clovis Oncology
- BeiGene
- Incyte
- Moderna
- G1 Therapeutics
- Seagen
- Natera
- Eisai
- National Institutes of Health
- Genentech
- EMD Serono
- Stand Up To Cancer
- Foundation Medicine
- Daiichi Sankyo Europe